Publicaciones en colaboración con investigadoras/es de Hospital Universitario de Salamanca (20)

2024

  1. Novel risk loci for COVID-19 hospitalization among admixed American populations

    eLife, Vol. 13

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

2022

  1. Novel genes and sex differences in COVID-19 severity

    Human molecular genetics, Vol. 31, Núm. 22, pp. 3789-3806

2010

  1. Análisis de las evidencias en la falsificación de medicamentos a nivel global

    Congreso Nacional Farmacéutico (17º. Bilbao. 2010)

1993

  1. Metabolism of ketamine in rat gut and brain microsomial fractions.

    European Congress of Biopharmaceutics and Pharmacokinetics (5º. Bruselas. 1993) : Participants' papers

1992

  1. Cimetidine versus ranitidine : the effect on the pharmacokinetics of theophylline ininsolated perfused rat liver

    Symposium of the International Society for the study of xenobiotics (Bolonia. 1992) : proceedings

  2. Efecto de dosis equimoleculares de cimetidina y ranitidina sobre la eliminación deteofilina

    Reunión Científica de la Asociación de Docentes de Farmacia Galénica (1º. Madrid. 1992)

1991

  1. Biotransformation kinetics of binifibrate and identification of its metabolites

    Bolletino Chimico Farmaceutico, Vol. 130, pp. 172-177

  2. Influence of excipient in the release of ketamine from suppositories

    Bolletino Chimico Farmaceutico, Vol. 130, pp. 52-54

  3. Pharmacokinetics of dibenzylamine administered as a drug delivery system withcefazoline

    Biopharmaceutics and Drug Disposition, Vol. 11, pp. 259-264

1989

  1. Determination of low concentrations of dibenzylamine in human plasma and urine bygas chromatography with a nitrogen phosphorus detector

    Journal of Chromatography. Biomedical Applications, Vol. 490, pp. 206-212

1988

  1. Choice of optimum pharmacokinetic model of orally administered paracetamol

    Biopharmaceutics and Drug Disposition, Vol. 9, pp. 389-396

1987

  1. Contribución del Servicio de Farmacia en un programa de tratamiento deheroinómanos.

    Congreso Nacional de la Asociación Nacional de Farmacéuticos de Hospitales. (32. Salamanca. 1987)

  2. Estudio de bioequivalencia de dos formulaciones orales de paracetamol

    Farmacia Hospitalaria XXXII. Tomo I (Madrid : Asociación Española de Farmacéuticos de Hospitales, 1987), pp. 117-123

  3. Monitoring of serum levels of amitriptyline in overdose.

    Proceedings del III Congreso Europeo de Biofarmacia y Farmacocinética

  4. Pharmacokinetics and Clinical evaluation of ketamine administered by the IV andepidural routes

    International Journal of Clinical Pharmacology,Therapy and Toxicology, Vol. 25, pp. 77-80

1986

  1. Bioavailability of amoxapine in experimental animals

    Bolletino Chimico Farmaceutico, Vol. 135, pp. 307-311

  2. Urinary and Biliary excretion kinetics of ketamine and its metabolites in the rabbit

    Bolletino Chimico Farmaceutico, Vol. 125, pp. 357-361

1985

  1. Pharmacokinetics of amoxapine and its active metabolites

    International Journal of Clinical Pharmacology, Therapy and Tox., Vol. 23, pp. 180-185

1984

  1. Farmacocinética de amoxapina y sus metabolitos activos en voluntarios sanos tras laadministración de una dosis de 100 mg

    Proceedings del II Congreso Europeo de Biofarmacia y Farmacocinética. Vol III